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Summary Prostaglandins of the A series (PGAs) have been previously shown to inhibit the growth and to
stimulate the differentiation of Friend erythroleukaemic cells (FLC) in vitro. In the present report we analysed
the effect of PGA treatment in vitro on FLC tumorigenicity, and in vivo on FLC proliferation and on natural
killer (NK) activity. PGA, pretreatment of FLC in vitro for 5 days before inoculation into syngeneic mice
slightly delayed tumour appearance, but did not significantly alter the pattern of tumour growth or mice
survival, indicating that PGA,, at least in the conditions studied, did not affect FLC tumorigenicity. Daily
treatment of mice with a long-acting synthetic analogue of PGA2 (16, 16 dimethyl-PGA2-methyl ester,
di-M-PGA2) delayed tumour appearance, inhibited tumour growth, as measured by tumour weight and
diameter, and increased the median mice survival time by 15-35%, depending on the schedule of treatment.
Daily treatment with di-M-PGA2 strongly suppressed NK activity in normal mice but had no significant effect
in tumour-bearing immunodepressed mice. PGA treatment of effector or target cells in vitro, or PGA added
during the NK assay, had no effect on NK activity. We suggest that the chemotherapeutic effect of PGA is
due to a direct action on tumour cell replication rather than to a stimulation of the host NK activity.
Since the first observation that tumour tissue produces much
larger amounts of prostaglandins (PGs) than normal tissue
(Jaffe et al., 1971), there has been a great deal of research
aimed at evaluating the relationships between PGs and
tumour cell growth and functions. PGs are known to be
involved in regulating cell proliferation and differentiation in
a large number of systems in vitro and in vivo. However, their
action varies with the molecular structure, the dose and the
animal model (for reviews see Jaffe & Santoro, 1977; Honn et
al., 1981; Garaci et al., 1987b). In particular prostaglandin A,
E and D compounds (PGAs, PGEs and PGDs respectively)
inhibit the growth and/or stimulate the differentiation of
several animal and human leukaemic cell lines, among which
are WEHI-3B-D- mouse myelomonocytic leukaemia
(Moore, 1982), L-1210 mouse leukaemia (Narumiya &
Fukushima, 1985), Ml mouse myeloid leukaemia (Honma et
al., 1980), HL-60 human promyelocytic leukaemia (Breitman,
1987), U-937 human lymphoma (Olsson et al., 1982) and
K562 human erythroleukaemia (Santoro et al., 1986, 1989;
Santoro, 1987). PGs also have been shown to play a role in
controlling the growth and differentiation of normal eryth-
roid precursors, and PGE and PGA compounds were found
to stimulate erythropoiesis in vivo and in vitro (for a review
see Santoro & Jaffe, 1990).
For several years we have studied the role of prostaglan-
dins in the modulation of growth and differentiation of the
virus-induced murine Friend erythroleukaemia cells (FLC).
These cells grow indefinitely in suspension culture and can be
induced to differentiate in vitro from a pro-erythroblast-like
to a normoblast-like stage that produces haemoglobin upon
stimulation with dimethylsulfoxide (DMSO) and several
other agents (Santoro & Jaffe, 1982).
FLC inoculated intravenously (i.v.) into DBA/2 mice pro-
duces a malignant disease characterised by leukaemic cell
infiltration of marrow, lymph nodes, liver and spleen (Preisler
et al., 1976). After subcutaneous (s.c.) inoculation, they pro-
duce s.c. tumours similar to myeloblastomas, which cause the
death of the animals within 3-7 weeks. Differentiating FLC,
i.e. FLC pretreated in vitro with DMSO, produce smaller
tumours and permit longer mouse survival than do
undifferentiated cells (Friend et al., 1971; Preisler et al.,
1976).
We have previously produced evidence that endogenous
PGE is involved in regulating FLC differentiation and pro-
liferation in vitro (Santoro et al., 1979a), and that a PGE2
analogue (16, 16-dimethyl-PGE2-methyl ester; di-M-PGE2)
inhibited FLC tumour growth in vivo and increased the
survival of mice injected s.c. with FLC (Santoro & Jaffe,
1979). We have also shown that PGA compounds are the
most effective PGs for inhibiting FLC proliferation in vitro,
and are the only PGs studied that can stimulate
differentiation in the absence of other inducers (Santoro et
al., 1979b).
The purpose of the present study was to determine whether
PGA-treatment could affect FLC tumorigenicity or FLC
proliferation in vivo. Since PGs can affect the immune re-
sponse (Goodwin & Webb, 1980), we also examined the
effect of PGA on the activation of natural killer cells in vitro
and in vivo. While the natural PGA compounds were used in
vitro, for in vivo studies we used a long-acting synthetic
analogue ofPGA2, 16, 16-dimethyl-PGA2-methyl ester (di-M-
PGA2), which has the same activity as PGA, on FLC growth
and differentiation in vitro (Santoro & Jaffe, 1982), and in
which the presence of the two methyl groups in position 16
blocks degradation via 15-hydroxy-dehydrogenase (Pike &
Bundy, 1982).
Materials and methods
Cell culture
Friend erythroleukaemia (FLC, strain 745, cell line GM-86
from the Institute for Medical Research, Camden, NJ, USA),
K562 erythroleukaemia and YAC-I thymoma cell lines were
grown in RPMI 1640 medium (Flow Laboratories, UK),
supplemented with 15% fetal calf serum (FCS) or 10% heat-
inactivated fetal bovine serum (FBS) (Flow Laboratories),
respectively for FLC and K562 or YAC-l cells, glutamine
2 mM, penicillin 100 U ml-' and streptomycin 0.1 mg ml'
(Complete Culture Medium, CCM), in a humidified 5% CO2
atmosphere at 37°C. Cell numbers were determined with a
haemocytometer; s.e. for 5-10 counts of the same culture
varied from 2 to 6%. Cell viability, determined by vital dye
exclusion (trypan blue, 0.04%), ranged between 97 and
100%; it was not influenced by PGA, or ethanol added at the
concentrations used. PGA, (Sigma Chemicals Co., St Louis,
MO, USA) and di-M-PGA2, kindly provided by Dr J. Pike,
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the Upjohn Co. (Kalamazoo, MI, USA), were stored as
100% ethanolic stock solutions (2 mg ml-') at - 20°C
and diluted in RPMI 1640 (for in vitro treatment) or in
sterile 154 mM NaCl (for in vivo administration) just
before use. Control medium contained the same concentra-
tion of ethanol diluent (0.01%), which did not affect cell
viability, DNA, RNA or protein synthesis (Amici et al.,
unpublished).
Tumour inoculation
One hundred and twenty 6-week-old female DBA/2 mice
were weighed and injected s.c., under a light ether anaes-
thesia, in the right flank with 5 x 105 viable FLC in 0.2 ml
RPMI 1640 medium. Mice were randomised into groups of
10- 15 animals, and injected intraperitoneally (i.p.) with
100 jil of sterile saline solution containing 10% ethanol (con-
trol) or di-M-PGA2 in 10% ethanolic solution. As previously
reported (Favalli et al., 1980) ethanol diluent was not toxic
to the mice and did not significantly affect FLC tumour
growth. Tumour appearance was assessed by daily palpation,
and when tumours were >2 mm in diameter they were
measured daily in at least two dimensions by Vernier caliper;
the average of the smallest and the largest diameters was
calculated. For two-tailed statistical comparisons Student's
t test for unpaired data was used and P values of <0.05
were considered significant. Curves of rates of tumour
appearance and mice survival were compared with the use of
the two-tailed signed rank test for paired samples (Epistat
computer program) and P values of <0.05 were considered
significant.
5'Cr labelling ofcells and NK assay
NK activity was detected by using the NK-highly sensitive
YAC-I cell line. YAC-l thymoma was maintained in CCM.
Labelling of cells and measurement of NK activity were
performed as previously described (Marini et al., 1985). For
di-M-PGA2 treatment of target cells, YAC-1 cells
were suspended in 8 ml of CCM (106 cells ml-')
and then incubated overnight at 37°C in the presence
of 2 igml-l di-M-PGA2. Tumour cells were then washed
three times with phosphate buffer solution, pH 7.2
(PBS), counted, resuspended in CCM and used in
assays. In other experiments di-M-PGA2 (2Ag ml ')
was added to the medium during the test. As described
in the text, in one experiment K562 human erythroleuk-
aemic cells were used as targets and peripheral blood
lymphocytes from a healthy human donor were used as
attacker cells.
To prepare labelled target cells for cytotoxicity assays,
YAC-1 cells were removed from continuous culture, cent-
rifuged (250g for 10min) and resuspended in 0.1 ml of FBS.
After addition of 100 jlCi sodium chromate (5'Cr) (Amer-
sham International, Amersham, UK), the cells were
incubated for 1 h at 37°C in a 5% CO2 humidified atmo-
sphere. Labelled cells were washed three times with RPMI
1640 containing 10 mM HEPES, 2% heat-inactivated FBS
and 50 jig ml-' gentamicin, and then resuspended in another
aliquot of the same medium supplemented with 10% FBS
(Chromium Release Assay medium, CRA). The viable cell
number was then adjusted to 105 ml-'. Assays were per-
formed in U-shaped 96-well microtitre plates (Greiner C.A.
and Sohne, Nurtingen, FRG). After serial two-fold dilution
starting at 107 cells ml-', effector spleen cells were plated in
0.1 ml CRA and labelled target cells in 0.1 ml were added.
Plates were then incubated for 4 h at 37°C in a 5% CO2
incubator, centrifuged (800g for 10 min) and radioactivity in
0.1 ml of supernatant was measured in a Packard y scintilla-
tion counter. All assays were performed in quadruplicate and
four effector: target (E:T) ratios were employed. The baseline
5'Cr release was determined in microwells in which
splenocytes were replaced by unlabelled target cells (i.e.
autologous control, AC). The AC never exceeded 10% of the
total radioactivity incorporated by target cells. Results are
expressed as the percentage of specific lysis and calculated as:
% specific lysis = c.p.m. TS - c.p.m AC
c.p.m. TC
where c.p.m. TS is the mean value of the counts per minute
(c.p.m.) of the test sample in the presence of effector cells;
c.p.m. AC is the mean c.p.m. of the AC, and c.p.m. TC is the
mean c.p.m. corresponding to the total amount of 5'Cr incor-
porated into target cells.
Results
PGA effect on FLC tumorigenicity
Friend erythroleukaemic cells derived from a logarithmically
growing population, were plated at a density of 2.5 x 105
cells ml-' in CCM, and PGA, (2 jigml-') or ethanol diluent
were added. Treatment with PGA, was not repeated during
the experiment. As it has been previously reported (Santoro
et al., 1979b) PGA, only partially inhibited the proliferation
of FLC derived from a logarithmically growing population.
In fact, if treatment was not repeated after 48 h, in contrast
to FLC derived from stationary-phase cultures, these cells
regained their growth potential and no significant inhibition
of cell proliferation was found after 96 h of PGA, treatment
(data not shown). After 5 days the cells were counted,
washed twice in PBS, resuspended in RPMI 1640 devoid of
FCS, and inoculated s.c. into DBA/2 mice (5 x 105 cells per
mouse) as described in Materials and methods. The rate of
tumour appearance, the pattern of tumour growth and
mouse survival rate were compared with those of mice
injected with untreated FLC. Eight days after tumour
inoculation, 46% of the control animals showed a visible
tumour, compared with 6% of the mice injected with pre-
treated FLC (P<0.01).
This initial difference decreased in the following days and
almost completely disappeared 14 to 16 days after inocula-
tion (Figure la). PGA,-pretreatment of FLC had no
significant effect on mouse survival (Figure lb) or on tumour
growth (at day 16 post-injection the tumour diameters were:
18.4 ± 3.5 mm in controls and 14.9 ± 3.9 mm in PGA,-
pretreated mice, P<0.1).
Effect ofdi-M-PGA2 treatment in vivo
In two separate experiments untreated, undifferentiated FLC
derived from a logarithmically growing population were
injected in DBA/2 mice as previously described. After 2-3 h
the mice were randomised (10-15 mice per group) and
injected i.p. with 1001il of sterile 154mM NaCl containing
10ljg di-M-PGA2. Injections were repeated daily up to day
21 p.i. (protocol A), or to day 16 (protocol B). Control mice
were treated with the same amount of diluent. Tumour
appearance was slightly delayed by di-M-PGA2 treatment (6
days p.i. visible tumours were present in 75% of PG-treated
as compared to 92% of control mice in protocol A, and 80%
as compared to 100% of control in protocol B; P<0.01).
After appearance, the tumours grew rapidly in a rather
uniform spherical shape, and their diameters were measured
daily (Figure 2a, b). In protocol B at day 16p.i. the mice
were killed and tumours were removed and weighed. Results
are illustrated in Table I. Di-M-PGA2 treatment reduced the
rate of tumour growth measured both as tumour diameter
(P<0.05) and tumour weight (P<0.02). PG-treatment, even
though it caused diarrhoea in the first hour after injection,
did not alter the weight of tumour-bearing (Table I) or
normal DBA/2 mice (after 15 days of treatment the weights
were: 16.1 ± 0.85 g in the controls and 16.73 ± 0.09 g in the
di-M-PGA2-treated mice).
Di-M-PGA2 treatment increased mouse survival. Figure 3
shows the survival curves of animals that had been injected
with di-M-PGA2 (10jig per injection) once daily for 21 days
(group I, Figure 3a), or twice daily for 13 days, followed by396 S. MARINI et al.
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Figure 1 Effect of PGA, treatment in vitro on the tumorigenicity
of undifferentiated FLC. FLC treated for 5 days with PGA,
(2 fig ml- ', only once after plating, * ), or control diluent
(0 O) were inoculated into two groups of 14 mice each. a,
The rate of tumour appearance. In mice that received PGA,-
treated FLC, the appearance of tumours was delayed (P<0.01).
b, Mouse survival. No difference in per cent survival was
observed between the two groups, up to 100 days post-injection.
one injection per day for a further 10 days (group II, Figure
3b). Median survival was increased by 15% in group I
(P<0.01) and by 35% in group II (P<0.005). However,
while it significantly increased mice median survival, treat-
ment with the twice daily dose of di-M-PGA2 had no effect
on tumour appearance (day 6 p.i.: controls = 54%; di-M-
PGA2 = 46%; P<0.5), possibly due to an effect on the
immune system in the first days after tumour inoculation,
when the animals are not yet immunodepressed by tumour
growth.
Measurement ofNK activity in normal and tumour-bearing
mice after di-M-PGA2 treatment
In order to evaluate whether the anti-tumour effect of di-M-
PGA2 is mediated by a modulation of NK activity, 36 five-
week-old mice were inoculated s.c. with 5 x 105 Friend eryth-
roleukaemic cells, in two separate experiments, and treated
with di-M-PGA2 (10 ig per day per mouse) or control
diluent for the following 15 days; 14 animals not inoculated
with FLC were randomly divided into two groups and
treated identically. Spleens from control and tumour-bearing
Figure 2 Effect ofdi-M-PGA2 treatment in vivo on FLC tumour
growth. a, 24 mice were inoculated with 5 x 105 FLC and divided
into two groups which received either di-M-PGA2 (1O iLg per day
per mouse, n = 12, 0 0) or control diluent (n = 12,
* *) up to 21 days post-injection. Data are expressed as
mean tumour diameter ± s.d. (P<0.05 on days 10, 14). b, After
FLC inoculation (5 x 105 cells per mouse) 20 mice were divided
into two groups and treated with di-M-PGA2 (1Ofig per day per
mouse, 0 O, n = 10) or control diluent ( , n = 10)
for 16 days. Tumours from di-M-PGA2-treated mice were smaller
than controls (P<0.05 on days 14, 16).
Table I Effect ofdi-M-PGA2 treatment on FLC tumour growth
Control Di-M-PGA2 % inhibition
Tumour diameter (mm) 21.40 ± 1.18 15.02 ± 2.02* 30
(mean ± s.d.) (n = 11) (n= 11)
Tumour weight (g) 2.03 ± 0.51 1.14 + 0.33** 44
(mean ± s.d.) (n = 5) (n= 5)
Total body weight (g) 17.28 ± 0.32 16.87 ± 0.82
(mean ± s.d.) (n = 18) (n= 18)
Measurements oftumour diameters and weights were determined on
day 16 after tumour inoculation. *P<0.05; **P<0.02.
animals were collected after 15 days of treatment. Figure 4
shows that at 15 days p.i. the NK activity was 45% less in
animals inoculated with FLC compared to normal controls
(P<0.02). Di-M-PGA2 treatment strongly suppressed (52%)
NK activity in normal mice but it did not further decrease
the depressed NK activity in tumour-bearing mice (Figure
4b).
In order to investigate whether the immune-modulating
action ofdi-M-PGA2 could be mimicked in vitro, the effect of
di-M-PGA2 was studied on NK activity either by separately
treating effector and target cells or by adding di-M-PGA2
directly during NK assay. Spleen cells (106ml-' in 10ml
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Figure 3 Effect of di-M-PGA2 treatment in vivo on survival of
mice injected with undifferentiated FLC. a, Di-M-PGA2 treat-
ment (10 g per day per mouse, n = 12), was started on the day
of tumour inoculation (5 x 105 cells per mouse) and continued
for 21 days. Mean survival was higher in di-M-PGA2-treated
(A\ A) as compared to control (A A) mice (P<0.01). b,
Di-M-PGA2 treatment (10ljg per mouse) was started on the day
of tumour inoculation and repeated twice daily for the first 13
days and once daily for a further 10 days. Control mice received
ethanol diluent following the same schedule. Per cent survival
was increased in di-M-PGA2-treated mice (A A, n = 11)
compared to controls (A A, n = I1) (P<0.005).
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Figure 4 Effect of di-M-PGA2 treatment in vivo on NK activity
of normal or tumour-bearing animals. Normal or FLC-
inoculated mice were treated with di-M-PGA2 (10jg per mouse
per day) or ethanol diluent for 15 days after tumour inoculation.
The last day of treatment mice were killed, the spleens were
collected and NK activity was measured in both normal (a) and
tumour-bearing (b) animals either untreated (0 0) or treated
with di-M-PGA2 (@ 0). Four mice were tested for each
group and each mouse was tested individually in quadruplicate.
NK activity was lower in di-M-PGA2-treated normal mice
(P<0.02) but the analogue had little or no effect in
immunodepressed tumour-bearing animals.
Finally, addition of di-M-PGA2 (2 jigml-') or ethanol
control during the NK test (with YAC-1 cells) did not cause
any change in the cytotoxicity (controls 26.2 ± 0.9%; ethanol
controls 27.8 ± 1.3%; di-M-PGA2 29.1 ± 1.2% cytotoxicity;
E:T ratio 100:1).
CCM) from normal animals were treated in vitro for 4 h with
2 jig ml1' di-M-PGA2 or control diluent and thereafter used
as attacker cells in the NK assay. This short-term in vitro
di-M-PGA2 treatment did not modulate NK activity
(25.4 ± 0.9% cytotoxicity in controls versus 24.0 ± 0.3%
cytotoxicity in PG-treated spleen cells, E:T ratio 100:1). NK
activity of splenocytes tested after 20h of incubation with
di-M-PGA2 or control solutions was too low to be measured.
Further experiments have been performed which demon-
strate that di-M-PGA2 activity was not due to a modulation
of NK susceptibility in target tumour cells. YAC-1 cells or
the human erythroleukaemia K562 cells (106 cells ml-') were
treated overnight with di-M-PGA2 (2 jig ml-') and used as
targets for NK assay, after 5'Cr-labelling. Di-M-PGA2-
treated target cells showed similar NK susceptibility com-
pared to control cells (for YAC-1 target cells: controls
34.5 ± 1.7%, di-M-PGA2 34.8 ± 1.4% cytotoxicity; for K562
target cells: controls 77.7 ± 0.8%, di-M-PGA2 75.6 ± 1.0%
cytotoxicity; E:T ratio 100:1).
Discussion
The results described in this paper show that systemic
administration of a long-acting analogue of PGA2, di-M-
PGA2, inhibited FLC tumour growth in vivo. All the
variables measured, i.e. tumour time of appearance, diameter
and weight, were reduced by PG-treatment while the length
of survival of PG-treated mice was increased. These effects
were similar to those obtained with di-M-PGE2 in vivo (San-
toro & Jaffe, 1979); they were dose-dependent and occurred
at doses that did not produce weight loss in the mice. On the
other hand, when FLC treated in vitro with PGA, (2 jigml-')
were injected into DBA mice, even though the time of
tumour onset was slightly delayed, no difference in the rate
of tumour growth or in mice survival was found.
The anti-tumour activity of PGA compounds has been
previously reported in different animal models in vitro and in
vivo. In 1973 Adolphe et al. reported that PGA2 inhibited
HeLa cell proliferation as measured by mitotic and398 S. MARINI et al.
metaphasic indices and Eisenbarth and Lebovitz (1974)
showed inhibition of chondrosarcoma growth by PGAI.
PGA compounds also inhibit murine and human melanoma
growth and human breast cancer cells in a concentration-
dependent manner in vitro (Bregman & Meyskens, 1983;
Shahabi et al., 1987). In in vivo studies Stein-Werblowsky
(1974) showed that PGA2 inhibited tumour-take and growth
in Wistar rats injected with benzopyrene-induced tumour
cells. Subcutaneous injections of PGA, (40mgkg-'day-')
suppressed by 20% the growth of established human
melanoma tumours in athymic nude mice, while higher doses
(100-200 mg kg-' day-') produced an 80% reduction in
tumour size (Bregman et al., 1986). Reversible toxicity (diarr-
hoea and skin inflammation) was associated with these higher
doses.
We have previously shown that PGA, (10 yg day-') sub-
stantially inhibited the rate of tumour growth in C57B1 mice
inoculated with B16 melanoma, in association with a stimula-
tion of the humoral and the cellular immune response
(Favalli et al., 1980). The role of prostaglandins in the
regulation of immune response has been studied in detail (for
reviews see Goodwin & Webb, 1980; Garaci et al., 1987b).
Voth et al. (1986) found that injection of two cyclo-
oxygenase inhibitors, indomethacin and aspirin, into the
peritoneal cavity of mice markedly induced natural killer cell
activity. PGE2 injection counteracted the indomethacin-
induced activation of NK cells. On the other hand, the type
of effect of PGA compounds on NK activity in vitro (Bank-
hurst, 1982) was concentration-dependent: doses of 10-6 M
were suppressive and 10-'° M caused slight stimulation.
We therefore studied the effect of di-M-PGA2 treatment on
the activity of NK cells, which are considered to play an
important role in immunosurveillance against tumour cells
(Hanna & Burton, 1981), in normal and FLC tumour-
bearing DBA mice. NK activity was profoundly suppressed
in tumour bearing mice as compared to control animals.
Di-M-PGA2, similarly to PGE2 (Garaci et al., 1987a),
inhibited by 50% the NK activity of normal mice, but had
no significant effect on the NK activity of immunodepressed
tumour-bearing animals.
Pretreatment of effector cells or addition of di-M-PGA2 at
concentrations as high as 4jLg ml1i during the NK assay had
no effect on NK activity, thus excluding a direct action of
di-M-PGA2 in this system. The possibility that PGA might
modulate the NK susceptibility of tumour target cells (e.g. by
alterating membrane fluidity) has also been tested. In vitro
pre-treatment of YAC-1 or K562 target cells with PGA, did
not change NK susceptibility.
The possibility that di-M-PGA2 exerts its chemotherapeutic
properties by modulating other functions of the immune
system cannot be excluded, but these data, together with the
observation that PGA compounds inhibit FLC proliferation
in vitro (Santoro et al., 1979b), suggest that di-M-PGA2 could
be acting directly on tumour cell replication. PGA anti-
proliferative activity has been shown to compare favourably
with standard cytotoxic chemotherapeutic drugs (Honn &
Marnett, 1985). However, even though it has been shown
that PGAs enter into the cells and are transported to the
nuclei (Fukushima et al., 1989), their mechanism of action is
not known. We have recently shown that PGA compounds
potently inhibit the replication of human K562 eryth-
roleukaemic cells (Santoro et al., 1986) and this action was
not mediated by cAMP, in agreement with results previously
reported in other systems (Hughes-Fulford et al., 1985). In
K562 cells PGA compounds did not directly alter DNA
synthesis, but partially inhibited protein synthesis and
glycosylation. PGA also induced the synthesis of a polypeptide
of 74 kDa, which has now been identified as a heat shock
protein (HSP) related to the major HSP70 group and which
appears to be associated with inhibition of cell proliferation
(Santoro et al., 1989). The possibility that similar alterations
in protein synthesis and maturation could be responsible for
PGA-induced inhibition of FLC replication is under inves-
tigation. A better understanding of the mechanism by which
prostaglandins inhibit cell proliferation could be useful in
helping to design new drugs for cancer chemotherapy.
We thank Dr J. Pike for kindly supplying di-M-PGA2. This work
was partially supported by the CNR-National Science Foundation,
USA-Italy Cooperative Program, Grant no. 8803273.
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